{"id":"folfifinox","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"FOLFIRINOX is a combination of the chemotherapy drugs folinic acid, fluorouracil, irinotecan, and oxaliplatin. This regimen works by interfering with the DNA replication process in cancer cells, ultimately leading to cell death.","oneSentence":"FOLFIRINOX is a chemotherapy regimen that combines four different drugs to target rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:31.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT02125136","phase":"PHASE2","title":"Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-11","conditions":"Ductal Adenocarcinoma of the Pancreas","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"FOLFIFINOX","genericName":"FOLFIFINOX","companyName":"AIO-Studien-gGmbH","companyId":"aio-studien-ggmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFIFINOX is a chemotherapy regimen used to treat Ductal Adenocarcinoma of the Pancreas. It is composed of the interventions Gem/nab-Pac and FOLFIRINOX, which are part of a clinical trial (NCT02125136) investigating intensified neoadjuvant chemotherapy in locally advanced pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}